Pending testing results, page-262

100% and 100% raises eyebrows in many and is thought to be possible only with few samples involved.

Announcement 10 February 2021:
"....SubB2M can be used to detect all stages of ovarian cancer with 100% specificity and 100% sensitivity."
"Dr Lucy Shewell from Griffith University’s Institute for Glycomics at the ANZGOG Conference. Dr Shewell reported that serum from 47 patients with all stages of ovarian cancer had significantly elevated mean levels of Neu5Gc glycans compared to 22 cancer-free control individuals."
"Griffith University’s Professor Mike Jennings said: “The SubB2M technology has proved to have remarkable sensitivity and specificity for detection of these aberrant sugar blood biomarkers in the case of ovarian cancer and we look forward to working with BARD1 to get this test into clinical use”.

Publication in 2018:
Biochemical and Biophysical Research Communications Volume 507, Issues 1–4, 9 December 2018, Pages 173-177. Title: Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M. Author: L.K.Shewell, aJ.J.WangaJ.C.PatonbA.W.PatonbC.J.Daya, M.P.Jennings.



The figure in this paper in my eyes shows an overlap of Normal and Stage I and Stage II. The table shows 22 Normal and 47 ovarian cancer (12+11+10+14).
How did it get much better from 2018 to now ?
Important to see how this test turns out on more samples and different cancers.